This Biotech Stock Just Slumped On A $48 Million Gene-Therapy DealInvestors Business Daily • 11/14/19
Sarepta and StrideBio Announce Multi-target Strategic Collaboration to Advance Novel Gene TherapiesGlobeNewsWire • 11/14/19
Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/08/19
Does This Beleaguered Biotech Stock Have A Winner In Gene Therapy?Investors Business Daily • 10/04/19
Sarepta Therapeutics Announces Positive Functional Results from the SRP-9003 (MYO-101) Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E, or Beta-SarcoglycanopathyGlobeNewsWire • 10/04/19
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 09/30/19
Why Is Sarepta Therapeutics (SRPT) Down 33.1% Since Last Earnings Report?Zacks Investment Research • 09/06/19
Sarepta Therapeutics to Present at the Morgan Stanley 17th Annual Global Healthcare ConferenceGlobeNewsWire • 09/03/19
After The Dust Has Settled, Key Sarepta Therapeutics Insiders Are Still Buying Shares And So Should InvestorsSeeking Alpha • 08/30/19
Sarepta May Have Lost The Battle For Latest FDA Approval Of DMD Drug, But It Will Win The WarSeeking Alpha • 08/22/19
Why Analysts Are Upbeat On Sarepta Despite A Notable FDA RejectionInvestors Business Daily • 08/22/19